Compare Aurobindo Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs CADILA HEALTHCARE - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA CADILA HEALTHCARE AUROBINDO PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 18.4 29.5 62.3% View Chart
P/BV x 4.0 5.2 77.0% View Chart
Dividend Yield % 0.3 0.7 39.6%  

Financials

 AUROBINDO PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
CADILA HEALTHCARE
Mar-20
AUROBINDO PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs830352 235.6%   
Low Rs527207 255.3%   
Sales per share (Unadj.) Rs333.9139.2 239.8%  
Earnings per share (Unadj.) Rs40.411.8 343.0%  
Cash flow per share (Unadj.) Rs51.818.6 278.7%  
Dividends per share (Unadj.) Rs2.503.50 71.4%  
Dividend yield (eoy) %0.41.3 29.4%  
Book value per share (Unadj.) Rs237.1101.4 233.9%  
Shares outstanding (eoy) m585.911,023.74 57.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.02.0 101.3%   
Avg P/E ratio x16.823.7 70.8%  
P/CF ratio (eoy) x13.115.0 87.1%  
Price / Book Value ratio x2.92.8 103.8%  
Dividend payout %6.229.8 20.8%   
Avg Mkt Cap Rs m397,569286,033 139.0%   
No. of employees `00017.913.4 133.2%   
Total wages/salary Rs m25,84924,145 107.1%   
Avg. sales/employee Rs Th10,956.910,632.7 103.0%   
Avg. wages/employee Rs Th1,447.71,801.2 80.4%   
Avg. net profit/employee Rs Th1,324.3898.5 147.4%   
INCOME DATA
Net Sales Rs m195,636142,531 137.3%  
Other income Rs m1,5531,139 136.4%   
Total revenues Rs m197,189143,670 137.3%   
Gross profit Rs m39,51924,198 163.3%  
Depreciation Rs m6,6806,965 95.9%   
Interest Rs m2,6263,418 76.8%   
Profit before tax Rs m31,76714,954 212.4%   
Minority Interest Rs m27288 9.4%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2693,198 227.3%   
Profit after tax Rs m23,64512,044 196.3%  
Gross profit margin %20.217.0 119.0%  
Effective tax rate %22.921.4 107.0%   
Net profit margin %12.18.5 143.0%  
BALANCE SHEET DATA
Current assets Rs m153,64587,154 176.3%   
Current liabilities Rs m120,42982,694 145.6%   
Net working cap to sales %17.03.1 542.6%  
Current ratio x1.31.1 121.1%  
Inventory Days Days13571 189.3%  
Debtors Days Days6494 67.9%  
Net fixed assets Rs m103,909133,236 78.0%   
Share capital Rs m5861,024 57.2%   
"Free" reserves Rs m138,322102,733 134.6%   
Net worth Rs m138,908103,757 133.9%   
Long term debt Rs m1,80032,146 5.6%   
Total assets Rs m264,544236,866 111.7%  
Interest coverage x13.15.4 243.7%   
Debt to equity ratio x00.3 4.2%  
Sales to assets ratio x0.70.6 122.9%   
Return on assets %9.96.5 152.1%  
Return on equity %17.011.6 146.6%  
Return on capital %23.813.7 173.6%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31652,752 184.5%   
Fx outflow Rs m40,58914,504 279.8%   
Net fx Rs m56,72738,248 148.3%   
CASH FLOW
From Operations Rs m16,22025,054 64.7%  
From Investments Rs m-28,768-10,123 284.2%  
From Financial Activity Rs m19,191-10,942 -175.4%  
Net Cashflow Rs m6,6563,989 166.9%  

Share Holding

Indian Promoters % 54.1 74.8 72.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 8.3 95.8%  
FIIs % 27.7 5.9 469.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 11.0 92.7%  
Shareholders   69,601 44,069 157.9%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  VENUS REMEDIES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher, Dow Futures Down by 28 Points(12:30 pm)

Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 74 points, up 0.2% at 48,877 levels.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 16, 2021 02:00 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ALEMBIC COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS